Reata Pharmaceuticals, Inc. Class Action Lawsuit - RETA

Company
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
Lead Plaintiff Deadline
December 14, 2020 (Expired)
Class Period
October 15, 2019 - August 7, 2020

Expired

Lead Plaintiff Deadline

Dec 14, 2020

Never Miss Another Deadline

Choose your preferred way to stay informed of new case launches and settlement deadlines

WhatsApp

Scan the QR code or click the button to join

Join on WhatsApp

Get Updates by Email

Required Field

Required Field

Required Field

No Spam, opt-out anytime, alert list is free

Allegations

(i) the MOXIe Part 2 study results were insufficient to support a single study marketing approval of omaveloxolone for the treatment of FA in the U.S. without additional evidence; (ii) as a result, it was foreseeable that the FDA would not accept marketing approval of omaveloxolone for the treatment of FA in the U.S. based on the MOXIe Part 2 study results; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Eligibility

In order to be eligible to join the RETA class action lawsuit, you must have incurred a loss on shares of Reata purchased during the class period listed above.

Lead Plaintiff Deadline

If you suffered a loss in Reata during the relevant time frame or pursuant to the relevant offering(s), you have until December 14, 2020 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

TOP